Ionis Pharmaceuticals (IONS) Convertible Debt (2009 - 2026)

Ionis Pharmaceuticals' Convertible Debt history runs 18 years deep, the most recent figure standing at $568.5 million for Q1 2026.

• In Q1 2026, Convertible Debt changed 0.5% year-over-year to $568.5 million; the TTM figure through Mar 2026 stood at $568.5 million (changed 0.5% YoY), while the FY2025 annual figure was $567.8 million, changed 0.5% from the prior year.
• Convertible Debt was $568.5 million for Q1 2026 at Ionis Pharmaceuticals, roughly flat from $567.8 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $627.7 million in Q3 2024 to a low of $114.1 million in Q2 2023.
• Historically, Convertible Debt has averaged $562.0 million across 5 years, with a median of $568.5 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Convertible Debt slumped 81.62% in 2023, then surged 394.08% in 2024.
• A 5-year view of Convertible Debt shows it stood at $622.2 million in 2022, then decreased by 9.64% to $562.3 million in 2023, then increased by 0.49% to $565.0 million in 2024, then grew by 0.5% to $567.8 million in 2025, then grew by 0.13% to $568.5 million in 2026.
• The last three Convertible Debt figures came in at $568.5 million (Q1 2026), $567.8 million (Q4 2025), and $565.7 million (Q1 2025), per Business Quant data.